Prophylactic Tumor Treating Fields in Management of Patients with Small Cell Lung Cancer
The goal of this study is to assess if the use of the Optune medical device for patients with small cell lung cancer helps reduce the chance of the cancer spreading to the brain. The Optune device is worn continuously on the head and generates electrical tumor-treatment fields.
Optune, tumor-treatment field, small cell lung cancer, extensive-stage, limited-stage.
Patients must be 22 years or older, have proven small cell lung cancer that has shown a positive response to treatment with chemotherapy and/or radiotherapy, have no other interfering cancers, and no implanted electrical devices.
22 - 100
Healthy Volunteers Needed
Duration of Participation
The active portion of the study will involve up to one month of screening and followed by 12 months using the Optune device. Follow-up will be the standard of care for cancer and will be up to 5 additional years.
John Minger, CCRC
OHSU Radiation Oncology